Introduction
============

Esophageal cancer (EC) ranks as the eighth most common cancer and is the sixth most common cause of death from cancer worldwide.[@b1-cmar-10-6167] Esophageal squamous cell carcinoma (ESCC), usually prevalent in Asia, accounts for about 90% of cases of EC.[@b2-cmar-10-6167],[@b3-cmar-10-6167] TNM staging is widely used as predictive models for prognosis in ESCC.[@b4-cmar-10-6167] However, the prognosis is usually very heterogeneous and unpredictable even in ESCC patients with same stage or similar pathologic features. It would be of great value to identify useful complementary biomarkers to stratify ESCC patients with high risk and to improve individualized treatment.

Recent evidence suggested that a systemic inflammatory response is associated with tumor development, apoptosis inhibition, angiogenesis promotion, and damage of DNA, thus resulting in tumor progression and metastasis.[@b5-cmar-10-6167] Various markers such as C-reactive protein (CRP) levels and blood neutrophil, lymphocyte, and platelet counts, either alone or expressed as ratios, might provide prognostic information on various cancers. Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) have recently been proposed as easily accessible inflammatory biomarkers.[@b5-cmar-10-6167],[@b6-cmar-10-6167] Although the prognostic role of NLR, PLR, and LMR and the prognosis of ESCC have been reported by many studies, inconsistent results have been presented. Previous meta-analyses have also investigated the prognostic role of NLR and PLR in EC. However, they also focused on one or two parameters (NLR and PLR). The prognostic role of LMR in ESCC has not been evaluated yet. What is more, after the publication of these meta-analyses, some new studies have been published. As a result, a meta-analysis is necessary to comprehensively evaluate the prognostic and clinicopathological significance of NLR, PLR, and LMR in patients with ESCC with updated evidence.

Materials and methods
=====================

Literature search
-----------------

A comprehensive literature search was conducted in the databases of PubMed, EMBASE, and Web of Science up to March 31, 2018. The following terms were used to identify studies: "NLR" ("neutrophil to lymphocyte ratio," "neutrophil-to-lymphocyte ratio," "neutrophil--lymphocyte ratio," "neutrophil/lymphocyte ratio") OR "PLR" ("platelet lymphocyte ratio," "platelet--lymphocyte ratio," "platelet to lymphocyte ratio," "platelet-to-lymphocyte ratio," "platelet/lymphocyte ratio") OR "LMR"("lymphocyte monocyte ratio," "lymphocyte--monocyte ratio," "lymphocyte to monocyte ratio," "lymphocyte-to-monocyte ratio," "lymphocyte/monocyte ratio") AND "ESCC" ("esophageal neoplasm," "esophageal cancer," "esophageal carcinoma," "esophageal squamous cell carcinoma").

Inclusion and exclusion criteria
--------------------------------

The following inclusion criteria were applied to identify eligible studies that: 1) involved pathologically confirmed ESCC; 2) had full texts published in English or Chinese; 3) evaluated the relationship between pretreatment NLR/PLR/LMR and survival outcomes or clinicopathological parameters, where survival outcomes included overall survival/cancer-specific survival (OS/CSS) and event-free survival (EFS), including progression-free survival, disease-free survival, and recurrence-free survival; 4) provided sufficient information to estimate HR or OR and their 95% CIs.

The exclusion criteria included the following: 1) cell line and animal studies, case reports, letters, reviews, or meta-analyses; 2) studies in which necessary data were not provided; 3) studies that reported HRs based on continuous NLR/PLR/LMR without a clear cutoff point; 4) overlapping studies and studies with low quality.

Data extraction
---------------

Two investigators (Sun and Zhang) independently reviewed the eligible studies and extracted the following data: surname of the first author, publication year, country, ethnicity, sample size, disease stage, histology type, cutoff value, and the outcomes. All data were then examined by the two investigators independently (Sun and Zhang). Disagreements were resolved by discussion.

Quality assessment
------------------

The quality of the methodology of the included studies was assessed by the Newcastle--Ottawa scale (NOS) recommended by the Cochrane Non-Randomized Studies Methods Working Group.[@b7-cmar-10-6167] Studies with five or more stars were defined as high quality studies. Quality assessment was performed by two investigators (Sun and Zhang) independently. Disagreements were resolved by discussion.

Statistical analysis
--------------------

The relationship between NLR/PLR/LMR and OS/CSS or EFS was measured by the combined HRs and their 95% CIs extracted from each eligible study. The HR and its 95% CI in each eligible study were directly extracted from the report, or indirectly estimated by methods described by Tierney et al.[@b8-cmar-10-6167] The combined HRs were estimated graphically by forest plots. ORs and their 95% CIs were combined to estimate the relationship between NLR/PLR/LMR and clinicopathological parameters. The overall HR/OR and its 95% CI overlap 1 were considered statistically significant and indicated a worse effect for the group with high NLR/PLR/LMR. Heterogeneity between studies was detected by the Q test and the I^2^ metric (no heterogeneity: *I*^2^=0%--25%; moderate heterogeneity: 25%--50%; large heterogeneity: 50%--75%; and extreme heterogeneity: 75%--100%).[@b9-cmar-10-6167] If *P*≥0.10 in the Q test or I^2^\<50%, the fixed effect model (Mantel--Haenszel method) was used.[@b10-cmar-10-6167] Otherwise, random effect model analysis was conducted.[@b11-cmar-10-6167] Subgroup analysis by different analytical methods (cutoff value, sample size, treatment, and geographic region) was performed in the analysis of OS/CSS or EFS. In addition, publication bias was assessed by the method reported by Begg and Egger.[@b12-cmar-10-6167],[@b13-cmar-10-6167] All *P*-values were two-tailed and a *P*-value \<0.05 was considered statistically significant. Most of the statistical analyses in this study were conducted using the STATA software (version 11.2; StataCorp LP, College Station, TX, USA).

Results
=======

Literature search and study characteristics
-------------------------------------------

The initial search yielded 258 studies. After removing duplicate articles, 132 studies were left. On screening titles and abstracts, 77 studies were excluded because they obviously did not meet our selection criteria. The remaining 55 studies were further examined. After carefully reading the full articles, 29 studies were excluded: four meta-analysis studies, one letter, 12 studies that included adenocarcinoma or other subtypes of EC, two studies that did not provide outcomes of interest, two studies that did not provide the cutoff value of NLR/PLR/LMR, and eight studies with overlapping data. Finally, 26 studies including 8,586 ESCC patients were available for further analysis[@b14-cmar-10-6167]--[@b39-cmar-10-6167] ([Figure 1](#f1-cmar-10-6167){ref-type="fig"}). Among these, 23 studies reported NLR,[@b14-cmar-10-6167],[@b15-cmar-10-6167],[@b17-cmar-10-6167]--[@b23-cmar-10-6167],[@b26-cmar-10-6167]--[@b39-cmar-10-6167] 12 studies reported PLR,[@b15-cmar-10-6167],[@b18-cmar-10-6167]--[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b26-cmar-10-6167],[@b27-cmar-10-6167],[@b32-cmar-10-6167]--[@b34-cmar-10-6167],[@b36-cmar-10-6167],[@b39-cmar-10-6167] and LMR was reported by six studies.[@b16-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b24-cmar-10-6167]--[@b26-cmar-10-6167] All the included studies were carried out in Asia (15 studies in China, 10 studies in Japan, and only one study in Korea). The sample size of 16 studies was \>200,[@b14-cmar-10-6167],[@b15-cmar-10-6167],[@b17-cmar-10-6167],[@b18-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b24-cmar-10-6167]--[@b26-cmar-10-6167],[@b29-cmar-10-6167]--[@b34-cmar-10-6167],[@b37-cmar-10-6167] and the remaining 10 studies involved \<200 patients.[@b16-cmar-10-6167],[@b19-cmar-10-6167],[@b21-cmar-10-6167],[@b23-cmar-10-6167],[@b27-cmar-10-6167],[@b28-cmar-10-6167],[@b35-cmar-10-6167],[@b36-cmar-10-6167],[@b38-cmar-10-6167],[@b39-cmar-10-6167] Thirteen studies reported both survival and clinicopathological data,[@b15-cmar-10-6167],[@b16-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167]--[@b26-cmar-10-6167],[@b31-cmar-10-6167]--[@b34-cmar-10-6167],[@b37-cmar-10-6167] and the other 13 studies only reported survival data.[@b14-cmar-10-6167],[@b17-cmar-10-6167]--[@b19-cmar-10-6167],[@b21-cmar-10-6167],[@b27-cmar-10-6167]--[@b30-cmar-10-6167],[@b35-cmar-10-6167],[@b36-cmar-10-6167],[@b38-cmar-10-6167],[@b39-cmar-10-6167] Most studies[@b15-cmar-10-6167],[@b18-cmar-10-6167]--[@b34-cmar-10-6167],[@b37-cmar-10-6167] (n=19) involved surgery-based treatment, six[@b14-cmar-10-6167],[@b16-cmar-10-6167],[@b17-cmar-10-6167],[@b35-cmar-10-6167],[@b36-cmar-10-6167],[@b38-cmar-10-6167] used chemoradiotherapy (CRT), and one study involved both treatments.[@b39-cmar-10-6167] The blood cell counts used to evaluate NLR/PLR/LMR were obtained before treatment in all the included studies. The cutoff value of NLR in 23 studies ranged from 1.6 to 5; 13 studies[@b14-cmar-10-6167],[@b15-cmar-10-6167],[@b17-cmar-10-6167],[@b19-cmar-10-6167],[@b21-cmar-10-6167],[@b27-cmar-10-6167],[@b30-cmar-10-6167],[@b31-cmar-10-6167],[@b33-cmar-10-6167],[@b35-cmar-10-6167],[@b36-cmar-10-6167],[@b38-cmar-10-6167],[@b39-cmar-10-6167] had a cutoff value ≥3, and the remaining 10 studies[@b18-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b23-cmar-10-6167],[@b26-cmar-10-6167],[@b28-cmar-10-6167],[@b29-cmar-10-6167],[@b32-cmar-10-6167],[@b34-cmar-10-6167],[@b37-cmar-10-6167] had a cutoff value \<3. The cutoff value of PLR ranged from 103 to 244; five studies[@b15-cmar-10-6167],[@b19-cmar-10-6167],[@b26-cmar-10-6167],[@b33-cmar-10-6167],[@b39-cmar-10-6167] had a cutoff value ≥150, and seven studies[@b18-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b23-cmar-10-6167],[@b27-cmar-10-6167],[@b34-cmar-10-6167],[@b36-cmar-10-6167] had a cutoff value \<150. Among the six studies that reported LMR, the cutoff value ranged from 2.57 to 4.02. LMR ≥3.5 was reported by three studies,[@b16-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167] and the remaining three studies[@b24-cmar-10-6167]--[@b26-cmar-10-6167] reported LMR values \<3.5. All included studies were scored high (with six stars or more). The baseline characteristics of the included studies are presented in [Table 1](#t1-cmar-10-6167){ref-type="table"}. Details of blood testing time, treatment methods, and NOS score are presented in [Table S1](#SD1-cmar-10-6167){ref-type="supplementary-material"}.

The prognostic role of NLR in ESCC
----------------------------------

Twenty-two studies reported the relationship between NLR and OS/CSS in ESCC.[@b14-cmar-10-6167],[@b15-cmar-10-6167],[@b17-cmar-10-6167]--[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b23-cmar-10-6167],[@b26-cmar-10-6167]--[@b39-cmar-10-6167] The overall analysis suggested that high NLR was associated with worse OS/CSS (HR =1.54, 95% CI =1.39--1.74, *P*\<0.001, I^2^=53.9%, *P*=0.001). Eleven studies reported the relationship between NLR and EFS in ESCC.[@b14-cmar-10-6167],[@b15-cmar-10-6167],[@b17-cmar-10-6167]--[@b19-cmar-10-6167],[@b21-cmar-10-6167],[@b23-cmar-10-6167],[@b24-cmar-10-6167],[@b26-cmar-10-6167],[@b28-cmar-10-6167],[@b31-cmar-10-6167] Similarly, high NLR was associated with worse EFS (HR =1.34, 95% CI =1.22--1.46, *P*\<0.001, I^2^=20%, *P*=0.25) ([Table 2](#t2-cmar-10-6167){ref-type="table"} and [Figure 2](#f2-cmar-10-6167){ref-type="fig"}).

The following clinicopathological parameters extracted from studies were collected for analysis: sex,[@b15-cmar-10-6167],[@b18-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b23-cmar-10-6167],[@b26-cmar-10-6167],[@b27-cmar-10-6167],[@b31-cmar-10-6167]--[@b34-cmar-10-6167],[@b37-cmar-10-6167] tumor location,[@b15-cmar-10-6167],[@b18-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b23-cmar-10-6167],[@b26-cmar-10-6167],[@b27-cmar-10-6167],[@b31-cmar-10-6167]--[@b34-cmar-10-6167],[@b37-cmar-10-6167] differentiation,[@b15-cmar-10-6167],[@b18-cmar-10-6167],[@b22-cmar-10-6167],[@b26-cmar-10-6167],[@b27-cmar-10-6167],[@b31-cmar-10-6167]--[@b34-cmar-10-6167],[@b37-cmar-10-6167] depth of invasion (T),[@b18-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b23-cmar-10-6167],[@b26-cmar-10-6167],[@b27-cmar-10-6167],[@b31-cmar-10-6167]--[@b34-cmar-10-6167] tumor length,[@b15-cmar-10-6167],[@b26-cmar-10-6167],[@b33-cmar-10-6167] lymph node metastasis,[@b15-cmar-10-6167],[@b18-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b23-cmar-10-6167],[@b26-cmar-10-6167],[@b27-cmar-10-6167],[@b31-cmar-10-6167]--[@b34-cmar-10-6167] and TNM stage.[@b15-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b23-cmar-10-6167],[@b26-cmar-10-6167],[@b27-cmar-10-6167],[@b31-cmar-10-6167],[@b32-cmar-10-6167],[@b34-cmar-10-6167],[@b37-cmar-10-6167] We found high NLR was more common in males than in females (male vs female: OR =1.58, 95% CI =1.19--2.10, *P*=0.002); high NLR was associated with deeper depth of invasion (T3--T4 vs T1--T2: OR =1.95, 95% CI =1.46--2.60, *P*\<0.001), longer tumor length (≥3 vs \<3 cm: OR =2.82, 95% CI =1.67--4.77, *P*\<0.001), positive lymph node metastasis (yes vs no: OR =1.27, 95% CI =1.03--1.57, *P*=0.026), and advanced stage (III--IV vs I--II: OR =1.47, 95% CI =1.28--1.69, *P*\<0.001). No significant association was found in tumor location and differentiation ([Table 3](#t3-cmar-10-6167){ref-type="table"}).

The prognostic role of PLR in ESCC
----------------------------------

The relationship between PLR and OS/CSS was investigated by 12 studies.[@b15-cmar-10-6167],[@b18-cmar-10-6167]--[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b26-cmar-10-6167],[@b27-cmar-10-6167],[@b32-cmar-10-6167]--[@b34-cmar-10-6167],[@b36-cmar-10-6167],[@b39-cmar-10-6167] We found that ESCC patients with high PLR may have worse OS/CSS (HR =1.37, 95% CI =1.25--1.51, *P*\<0.001, I^2^=33.1%, *P*=0.125). The pooled analysis of five studies[@b15-cmar-10-6167],[@b18-cmar-10-6167],[@b19-cmar-10-6167],[@b26-cmar-10-6167],[@b31-cmar-10-6167] also suggested high PLR was associated with worse EFS (HR =1.27, 95% CI =1.07--1.52, *P*=0.007, I^2^=26.9%, *P*=0.242) ([Table 2](#t2-cmar-10-6167){ref-type="table"} and [Figure 3](#f3-cmar-10-6167){ref-type="fig"}).

Eight studies[@b15-cmar-10-6167],[@b18-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b26-cmar-10-6167],[@b32-cmar-10-6167]--[@b34-cmar-10-6167] reported the relationship between PLR and clinicopathological parameters. We also found that high PLR was associated with depth of invasion (T3--T4 vs T1--T2: OR =1.49, 95% CI =1.26--1.76, *P*\>0.001), tumor length (≥3 vs \<3 cm: OR =1.82, 95% CI =1.32--2.49, *P*\<0.001), lymph node metastasis (yes vs no: OR =1.53, 95% CI =1.20--1.96, *P*=0.001), and stage (III--IV vs I--II: OR =1.32, 95% CI =1.12--1.57, *P*=0.001). No association was found in sex, tumor location, and differentiation ([Table 3](#t3-cmar-10-6167){ref-type="table"}).

The prognostic role of LMR in ESCC
----------------------------------

The impact of LMR on OS/CSS was evaluated by six studies,[@b16-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b24-cmar-10-6167]--[@b26-cmar-10-6167] and three studies[@b16-cmar-10-6167],[@b24-cmar-10-6167],[@b26-cmar-10-6167] evaluated the relationship between LMR and EFS. The combined HR for OS/CSS and EFS suggested that high LMR might be associated with better survival (HR =0.70, 95% CI =0.54--0.89, *P*\<0.001 for OS/CSS; HR =0.65, 95% CI =0.43--0.99, *P*\<0.001 for EFS, respectively.) ([Table 2](#t2-cmar-10-6167){ref-type="table"} and [Figure 4](#f4-cmar-10-6167){ref-type="fig"}).

The relationship between LMR and clinicopathological parameters was evaluated by six studies.[@b16-cmar-10-6167],[@b20-cmar-10-6167],[@b22-cmar-10-6167],[@b24-cmar-10-6167]--[@b26-cmar-10-6167] Low LMR was associated with sex (male vs female: OR =0.61, 95% CI =0.37--1.00, *P*=0.049), tumor location (upper/middle vs lower: OR =1.23, 95% CI =1.03--1.46, *P*=0.021), depth of invasion (T3--T4 vs T1--T2: OR =0.58, 95% CI =0.48--0.69, *P*\<0.001), lymph node metastasis (yes vs no: OR =0.68, 95% CI =0.57--0.82, *P*\<0.001), and stage (III--IV vs I--II: OR =0.63, 95% CI =0.50--0.80, *P*\<0.001). No association was found in tumor differentiation and tumor length ([Table 3](#t3-cmar-10-6167){ref-type="table"}).

Subgroup analysis
-----------------

Subgroup analysis was further conducted according to cutoff value (≥3 vs \<3 for NLR, ≥150 vs \<150 for PLR, and ≥3.5 vs \<3.5 for LMR), sample size (≥200 vs \<200), treatment (surgery-based vs CRT only), and geographic region (China vs non-China). The results of the subgroup analyses are presented in [Table 2](#t2-cmar-10-6167){ref-type="table"}.

When the subgroup analysis was performed according to cutoff value, the HRs in studies with cutoff value ≥3 were 1.71 and 1.43 for OS/CSS and EFS, respectively, which were more significant than studies with cutoff value \<3 (HRs were 1.41 and 1.26 for OS/CSS and EFS, respectively). This suggested that the higher the NLR, the worse the prognosis of the patient. Also, the heterogeneity in studies with cutoff value ≥3 (I^2^=40.1% and 0.0% for OS/CSS and EFS, respectively) was lower than studies with cutoff value \<3 (I^2^=57.3% and 39.0% for OS/CSS and EFS, respectively). When the subgroup analysis was performed according to treatment (surgery-based vs CRT only) in OS/CSS, I^2^ decreased in both subgroups (I^2^=45.7% and 37.0% for surgery-based and CRT only studies, respectively). Treatment methods might be the source of heterogeneity. Other subgroup analyses suggested a significant association between high NLR and poor OS/CSS and EFS.

In studies exploring the prognostic role of PLR in ESCC, I^2^ in the overall analysis was 33.1% (*P*=0.125) for OS/CSS. When the subgroup analysis was performed according to cutoff value, both studies with cutoff value ≥150 and \<150 showed significant association. However, the heterogeneity in each group was reduced when compared with the overall analysis (I^2^=12.4%, *P*=0.36 for cutoff value ≥150; I^2^=26.0%, *P*=0.23 for cutoff value \<150). This may suggest that different cutoff values of PLR maybe one of the sources of heterogeneity.

Low LMR was associated with poor OS/CSS in all subgroup analyses. The heterogeneity in studies with sample size ≥200 was moderate (I^2^=49.5%, *P*=0.114), and no heterogeneity was observed in studies with sample size \<200 (I^2^=0.0%, *P*=0.70). As a result, the high heterogeneity (I^2^=64.0%, *P*=0.016) in the overall analysis might account for the subgroup analysis by sample size (≥200 and \<200).

Publication bias
----------------

Begg's and Egger's tests were applied for publication bias detection. Only the analysis of the effect of LMR on OS/CSS showed significant publication bias (*P*~Begg~ =0.02, *P*~Egger~ =0.05); other comparisons did not show any publication bias ([Table 2](#t2-cmar-10-6167){ref-type="table"}).

Discussion
==========

It is now generally recognized that inflammation response plays a critical role in tumor progression and may influence survival outcomes in patients with cancer. As systematic inflammatory markers, high neutrophil, platelet, and macrophage counts, low lymphocyte, and also high NLR, PLR, and low LMR have been recognized to be associated with unfavorable prognosis in solid tumors. In this meta-analysis, we comprehensively assessed the prognostic role of NLR, PLR, and LMR in ESCC by collecting the data set of 26 studies including 8,586 ESCC patients. We found that high NLR, PLR and low LMR were associated with poor survival and malignant phenotype such as deeper depth of invasion (T), positive lymph node metastasis (N), and advanced TNM stage. This preclinical and clinical research may lay the foundation for NLR, PLR, and LMR to serve as useful prognostic biomarkers and to stratify ESCC patients with high risk.

Previous meta-analyses have investigated the prognostic role of NLR and PLR in EC. Yang et al[@b40-cmar-10-6167] first investigated the relationship between NLR and EC by summarizing six studies involving 1,633 patients with EC. Yodying et al analyzed seven studies including 1,540 EC patients to investigate the prognostic role of NLR and PLR in EC.[@b41-cmar-10-6167] Huang et al[@b42-cmar-10-6167] focused on the relationship between NLR and ESCC. Nine studies with 2,513 patients were included in their study. In a study by Zhao et al,[@b43-cmar-10-6167] 16 studies including 6,699 patients were utilized to investigate the prognostic role of PLR in EC patients. All these meta-analyses found that high NLR and PLR were associated with poor survival in EC. Our study showed the following advancements when compared with previous work. Firstly, our study was more comprehensive than earlier work. Prior to this, the prognostic role of NLR was mostly investigated by meta-analyses. One study evaluated both NLR and PLR;[@b41-cmar-10-6167] PLR was investigated by one study.[@b43-cmar-10-6167] The prognostic role of LMR had not been investigated yet. As NLR, PLR, and LMR were the mostly studied inflammatory biomarkers, for the first time we comprehensively investigated the prognostic role of the three inflammatory markers (NLR, PLR, and LMR) in ESCC. We found all these three markers to be associated with tumor progression and prognosis of ESCC patients. Secondly, the sample size in our analysis was larger than any previous meta-analysis. Twenty-six studies including 8,586 ESCC patients were available in our study, which was larger than the study by Yang et al[@b40-cmar-10-6167] (1,633), Yodying et al[@b41-cmar-10-6167] (1,540), Huang et al[@b42-cmar-10-6167] (2,513), and Zhao et al[@b43-cmar-10-6167] (6,699). To some degree, our result was more robust and reliable than previous work. Lastly, as ESCC was a major type of EC (accounted for 90% of EC cases), we only focused on the prognostic role of NLR, PLR, and LMR on ESCC. This would reduce the potential bias induced by histology type. In a nutshell, our meta-analysis is more updated and comprehensive than previous works.

As ESCC is a complicated disease, many clinical variables or biomarkers are associated with the prognosis of ESCC, for example hemoglobin, CRP, squamous cell carcinoma antigen (SCC-Ag), fibrinogen, nutritional parameters, cell-free circulating tumor DNA, and circulating noncoding RNA. NLR, PLR, and LMR were just systemic inflammatory response-related markers that affected the prognosis of ESCC. In some cases, these factors may even contradict each other. For example, all NLR, PLR and LMR are high, how to determine the prognosis of ESCC? As no studies have reported such a case, and available data are insufficient to analyze this situation, we failed to explore the result. However, to predict the prognosis of ESCC more accurately and usefully, we think it is better to combine these useful biomarkers together just as the Glasgow prognostic score, an inflammation-based score which combined albumin and C-reactive protein (CRP).

Some limitations should also be acknowledged.

Firstly, the cutoff value of NLR/PLR/LMR varied in the included studies. The criteria and method used in different institutions to determine the cutoff value were different; we could not propose an appropriate cutoff value by statistical analysis. This may affect the results and induce unavoidable potential heterogeneity and bias. It may limit the usefulness of NLR/PLR/LMR in clinical practice. Therefore, a standard and uniform cutoff value defining NLR/PLR/LMR is needed. Secondly, some factors such as age, sex, smoking history, tumor stage, comorbidities, and treatment method may affect the level of NLR/PLR/LMR,[@b44-cmar-10-6167],[@b45-cmar-10-6167] and also the prognosis in ESCC. However, we could not conduct a stratified analysis to assess the effects of confounding factors on the prognostic role of NLR/PLR/LMR in ESCC patients because of the limited information provided in the original studies. Lastly, publication bias was detected in the comparison of LMR in OS. Apart from this, potential publication biases may exist. Studies that failed to get published because of negative or null results could not be identified in our literature search and thus were not included in this analysis. In addition, some reports that did not provide sufficient data were also excluded from our analyses of the publications.

In conclusion, our analysis suggested high NLR, PLR and low LMR were associated with poor survival and malignant phenotype in ESCC patients. With the limitations, heterogeneities, and bias of meta-analysis, our conclusions in this study need to be interpreted with caution. Future large prospective studies with rigorously designed methodologies are warranted to confirm our results.

Supplementary material
======================

###### 

Details of blood testing time, treatment methods, and NOS score of included studies

  Study                                      Blood exam time                   Treatment                   Quality assessment with NOS              
  ------------------------------------------ --------------------------------- --------------------------- ----------------------------- ---------- ------------
                                                                                                                                                    
  Yang et al (2018)[@b46-cmar-10-6167]       Before surgery                    Surgery ± adj CRT           **\*\*\***                    **\*\***   **\*\*\***
  Kunizaki et al (2018)[@b47-cmar-10-6167]   Before treatment                  Surgery/other               **\*\*\***                    **\***     **\*\***
  Sato et al (2017)[@b48-cmar-10-6167]       Before treatment                  CRT                         **\*\*\***                    **\***     **\*\***
  Kijima et al (2017)[@b49-cmar-10-6167]     Within 2 weeks before treatment   CRT                         **\*\*\***                    **\*\***   **\*\***
  Gao et al (2017)[@b50-cmar-10-6167]        Before treatment                  Surgery ± adj CRT           **\*\*\***                    **\*\***   **\*\***
  Miao et al (2017)[@b51-cmar-10-6167]       Before treatment                  CRT                         **\*\*\***                    **\*\***   **\*\***
  Zhou et al (2017)[@b52-cmar-10-6167]       Before CRT                        CRT                         **\*\*\***                    **\*\***   **\*\*\***
  He et al (2017)[@b53-cmar-10-6167]         Within 1 week before surgery      Surgery ± adj CRT           **\*\*\*\***                  **\*\***   **\*\*\***
  Liu et al (2017)[@b54-cmar-10-6167]        Within 1 week before CRT          CRT                         **\*\*\***                    **\*\***   **\*\***
  Zhang et al (2016)[@b55-cmar-10-6167]      Before CRT                        CRT                         **\*\*\***                    **\***     **\*\***
  Zhang et al (2016)[@b56-cmar-10-6167]      Within 5 days before surgery      Surgery ± adj CRT           **\*\*\***                    **\***     **\*\***
  Toyokawa et al (2016)[@b57-cmar-10-6167]   Before treatment                  ± NAC + surgery ± adj CMT   **\*\*\***                    **\***     **\*\*\***
  Hirahara et al (2016)[@b58-cmar-10-6167]   1 week before surgery             Surgery                     **\*\*\***                    **\*\***   **\*\*\***
  Ikeguchi et al (2016)[@b59-cmar-10-6167]   Before NAC/surgery                ± NAC + surgery ± adj CT    **\*\*\***                    **\***     **\*\***
  Geng et al (2016)[@b60-cmar-10-6167]       Before surgery                    Surgery                     **\*\*\*\***                  **\*\***   **\*\*\***
  Xiao et al (2016)[@b61-cmar-10-6167]       Within 2 weeks before CRT         Surgery ± adj CRT           **\*\*\*\***                  **\*\***   **\*\*\***
  Zhu et al (2017)[@b62-cmar-10-6167]        Within 3 days prior to surgery    Surgery ± adj CRT           **\*\*\***                    **\*\***   **\*\*\***
  Huang and Feng (2015)[@b63-cmar-10-6167]   Within 1 week before surgery      Surgery ± adj CRT           **\*\*\***                    **\***     **\*\*\***
  Han et al (2015)[@b64-cmar-10-6167]        Within 1 week before surgery      Surgery ± adj CRT           **\*\*\***                    **\*\***   **\*\*\***
  Ji et al (2016)[@b65-cmar-10-6167]         Before NAC                        NAC + S                     **\*\*\***                    **\***     **\*\*\***
  Jung et al (2016)[@b66-cmar-10-6167]       Within 1 week before surgery      Surgery ± adj CMT           **\*\*\***                    **\***     **\*\***
  Kosumi et al (2016)[@b67-cmar-10-6167]     Before NAC/surgery                ± NAC + surgery ± adj CMT   **\*\*\***                    **\***     **\*\***
  Arigami et al (2015)[@b68-cmar-10-6167]    Within 2 weeks before surgery     Surgery                     **\*\*\***                    **\***     **\*\*\***
  Duan et al (2015)[@b69-cmar-10-6167]       Within 1 week before surgery      Surgery                     **\*\*\***                    **\*\***   **\*\*\***
  Xie et al (2016)[@b70-cmar-10-6167]        Within 10 days before surgery     Surgery ± adj CMT           **\*\*\***                    **\***     **\*\***
  Feng et al (2014)[@b71-cmar-10-6167]       Within 1 week before surgery      Surgery                     **\*\*\***                    **\*\***   **\*\*\***

**Abbreviations:** NOS, Newcastle--Ottawa scale; CRT, chemoradiotherapy; CT, computed tomography; adj, adjuvant; S, surgery; NAC, neoadjuvant chemotherapy; CMT, chemoradiotherapy.

**Disclosure**

The authors report no conflicts of interest in this work.

![Flow diagram of studies selection procedure.\
**Abbreviations:** NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; EC, esophageal cancer; ESCC, esophageal squamous cell carcinoma.](cmar-10-6167Fig1){#f1-cmar-10-6167}
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![Forest plot of HR for the association of PLR with OS/CSS (**A**) and EFS (**B**) in patients with ESCC.\
**Abbreviations:** OS, overall survival; CSS, cancer-specific survival; EFS, event-free survival; ESCC, esophageal squamous cell carcinoma; PLR, platelet to lymphocyte ratio.](cmar-10-6167Fig3){#f3-cmar-10-6167}

![Forest plot of HR for the association of LMR with OS/CSS (**A**) and EFS (**B**) in patients with ESCC.\
**Abbreviations:** OS, overall survival; CSS, cancer-specific survival; EFS, event-free survival; ESCC, esophageal squamous cell carcinoma; LMR, lymphocyte to monocyte ratio.](cmar-10-6167Fig4){#f4-cmar-10-6167}

###### 

Main characteristics of all studies included in the meta-analysis

  Study                                       Ethnicity (country)   Case no   Gender (M/F)   Age     Stage                  NLR cutoff (positive, %)   PLR cutoff (positive, %)   LMR cutoff (positive, %)   Follow-up (months)   Outcome       NOS score
  ------------------------------------------- --------------------- --------- -------------- ------- ---------------------- -------------------------- -------------------------- -------------------------- -------------------- ------------- -----------
                                                                                                                                                                                                                                                
  Yang et al (2018)[@b34-cmar-10-6167]        East-Asian (China)    515       418/97         61      I--III                 1.2 (90.5)                 133 (40.8)                 NR                         35                   OS, C         8
  Kunizaki et al (2018)[@b39-cmar-10-6167]    East-Asian (Japan)    116       98/18          66      0--IV                  5 (10.3)                   150 (35.3)                 NR                         NR                   OS            6
  Sato et al (CRT; 2017)[@b35-cmar-10-6167]   East-Asian (Japan)    104       NR             65.3    Advanced               3 (51.0)                   NR                         NR                         NR                   OS            6
  Sato et al (FP; 2017)[@b35-cmar-10-6167]    East-Asian (Japan)    145       NR             63.6    Advanced               3 (41.4)                   NR                         NR                         NR                   OS            6
  Kijima et al (2017)[@b38-cmar-10-6167]      East-Asian (Japan)    98        86/12          64.9    III--IV                3 (38.8)                   NR                         NR                         15.4                 OS            7
  Gao et al (2017)[@b37-cmar-10-6167]         East-Asian (Japan)    1,281     988/293        NR      0--IV                  2.86 (41.3)                NR                         NR                         NR                   OS            7
  Miao et al (2017)[@b36-cmar-10-6167]        East-Asian (Japan)    168       134/34         67.15   II--IV                 3.34 (35.7)                103.75 (59.5)              NR                         33                   OS            7
  Zhou et al (2017)[@b14-cmar-10-6167]        East-Asian (China)    517       407/110        65      II--IV                 5 (61)                     NR                         NR                         17                   OS, PFS       8
  He et al (2017)[@b15-cmar-10-6167]          East-Asian (China)    317       268/49         60      I--IV                  3.3 (49.5)                 150 (30.9)                 NR                         19.2                 OS, DFS, C    8
  Liu et al (2017)[@b16-cmar-10-6167]         East-Asian (China)    162       127/35         63      II--III                NR                         NR                         4.02 (50)                  23.3                 OS, PFS, C    7
  Zhang et al                                 East-Asian            212       166/46         60      T N M 1--4 0--1 0--1   3 (38.2)                   NR                         NR                         17                   OS, PFS       6
  Zhang et al (2016)[@b18-cmar-10-6167]       East-Asian (China)    468       376/92         59.5    I--III                 2.5                        117                        NR                         49.1                 OS, DFS       6
  Toyokawa et al (2016)[@b19-cmar-10-6167]    East-Asian (Japan)    185       152/33         64      I--IV                  3.61 (11.9)                193 (17.3)                 NR                         81.5                 OS, RFS       7
  Hirahara et al (2016)[@b20-cmar-10-6167]    East-Asian (Japan)    468       132/15         66      I--III                 1.6 (74.8)                 147 (46.2)                 4 (56.5)                   NR                   CSS, C        8
  Ikeguchi et al (2016)[@b21-cmar-10-6167]    East-Asian (Japan)    84        73/11          65.7    I--III                 3 (31)                     NR                         NR                         35.5                 DFS           6
  Geng et al (2016)[@b22-cmar-10-6167]        East-Asian (China)    916       696/220        60      I--III                 1.7 (68.3)                 120 (50)                   3.57 (54.1)                39                   OS, C         9
  Xiao et al (2016)[@b23-cmar-10-6167]        East-Asian (China)    121       106/15         62      I--III                 1.77 (47.9)                NR                         NR                         28                   OS, RFS, C    9
  Zhu et al (2017)[@b24-cmar-10-6167]         East-Asian (China)    220       117/103        NR      T3N0M0                 NR                         NR                         3.36 (42.7)                53.25                OS, DFS, C    8
  Huang and Feng (2015)[@b25-cmar-10-6167]    East-Asian (China)    348       303/45         59.2    I--III                 NR                         NR                         2.93 (58.3)                NR                   CSS, C        7
  Han et al (2015)[@b26-cmar-10-6167]         East-Asian (China)    218       177/41         60.5    I--III                 2.6 (41.7)                 244 (12.4)                 2.57 (79.4)                NR                   OS, DFS, C    8
  Ji et al (2016)[@b27-cmar-10-6167]          East-Asian (China)    41        38/3           56.6    I--III                 5 (24.4)                   130 (63.4)                 NR                         NR                   OS            7
  Jung et al (2016)[@b28-cmar-10-6167]        East-Asian (Korea)    119       112/7          63.6    I--III                 2.97 (19.3)                NR                         NR                         28.68                OS, DFS       6
  Kosumi et al (2016)[@b29-cmar-10-6167]      East-Asian (Japan)    283       248/35         NR      I--IV                  1.94 (49.8)                NR                         NR                         33.6                 OS            6
  Arigami et al (2015)[@b30-cmar-10-6167]     East-Asian (Japan)    309       210/28         65      I--III                 3 (17.6)                   NR                         NR                         26                   OS            7
  Duan et al (2015)[@b31-cmar-10-6167]        East-Asian (China)    371       276/95         57      Ib--IIIc               3 (19.9)                   NR                         NR                         66                   CSS, RFS, C   8
  Xie et al (2016)[@b32-cmar-10-6167]         East-Asian (China)    317       244/73         58.1    I--III                 2.1 (46.7)                 103 (62.1)                 NR                         46                   CSS, C        6
  Feng et al (2014)[@b33-cmar-10-6167]        East-Asian (China)    483       411/72         59.1    I--III                 3.5 (36.8)                 150 (45.5)                 NR                         NR                   OS, C         8

**Abbreviations:** NOS, Newcastle--Ottawa scale; NR, not reported; C, clinicopathological parameters; CRT, chemoradiotherapy; CSS, cancer-specific survival; F, female; FP, 5-fluorouracil and cisplatin; M, male; OS, overall survival; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PFS, progression-free survival; DFS, disease-free survival; RFS, recurrence-free survival; NR, no report.

###### 

Meta-analysis results of NLR, PLR, and LMR and OS/CSS and EFS in patients with ESCC

                                   OS/CSS   EFS                                                                                                      
  -------------------------------- -------- ---------------------------- ------------- ------------- ---- ---------------------------- ------------- ------------
                                                                                                                                                     
  NLR                                                                                                                                                
  Overall                          22       1.54 (1.39, 1.74), \<0.001   53.9, 0.001   0.17, 0.06    11   1.34 (1.22, 1.46), \<0.001   20, 0.253     0.31, 0.17
  Subgroup analysis Cutoff value                                                                                                                     
  ≥3                               12       1.71 (1.47, 1.98), \<0.001   40.1, 0.07    0.16, 0.12    6    1.43 (1.25, 1.63), \<0.001   0.0, 0.516    1.00, 0.44
  \<3                              10       1.41 (1.21, 1.64), \<0.001   57.3, 0.01    0.37, 0.65    5    1.26 (1.11, 1.43), \<0.001   39.0, 0.161   0.81, 0.47
  Sample size                                                                                                                                        
  ≥200                             13       1.45 (1.28, 1.64), \<0.001   49.9, 0.02    0.95, 0.56    6    1.36 (1.20, 1.53), \<0.001   0.0, 0.693    0.45, 0.16
  \<200                            9        1.89 (1.47, 2.44), \<0.001   61.7, 0.01    0.86, 0.01    5    1.55 (1.09, 2.20), 0.015     56.8, 0.055   0.81, 0.23
  Treatment                                                                                                                                          
  Surgery-based                    15       1.43 (1.27, 1.61), \<0.001   45.7, 0.03    0.14, 0.27    9    1.31 (1.18, 1.46), \<0.001   22.2, 0.245   0.35, 0.09
  CRT                              7        1.78 (1.55, 2.04), \<0.001   37.0, 0.14    1.00, 0.63    2    1.41 (1.18, 1.69), \<0.001   42.8, 0.186   --
  Country                                                                                                                                            
  China                            14       1.48 (1.30, 1.69), \<0.001   55.0, 0.01    0.74, 0.75    8    1.41 (1.25, 1.58), \<0.001   4.9, 0.392    0.90, 0.47
  Non-China                        8        1.77 (1.39, 2.25), \<0.001   57.4, 0.02    0.92, 0.02    3    1.22 (1.05, 1.42), 0.011     33.7, 0.221   0.30, 0.59
  PLR                                                                                                                                                
  Overall                          12       1.37 (1.25, 1.51), \<0.001   33.1, 0.125   0.84, 0.32    5    1.27 (1.07, 1.52), 0.007     26.9, 0.242   0.62, 0.69
  Cutoff value                                                                                                                                       
  ≥150                             5        1.58 (1.33, 1.88), \<0.001   12.4, 0.36    0.46, 0.13    3    1.26 (1.00, 1.59), 0.05      10.5, 0.33    0.30, 0.26
  \<150                            7        1.29 (1.15, 1.44), \<0.001   26.0, 0.23    0.23, 0.14    2    1.72 (0.69, 4.29), 0.24      68.9, 0.07    --
  Sample size                                                                                                                                        
  ≥200                             7        1.40 (1.20, 1.64), \<0.001   51.2, 0.06    0.76, 0.51    3    1.25 (1.04, 1.51), 0.02      7.3, 0.34     1.00, 0.44
  \<200                            5        1.38 (1.03, 1.85), 0.03      3.9, 0.385    0.81, 0.07    2    1.73 (0.64, 4.68), 0.28      67.6, 0.08    --
  Treatment                                                                                                                                          
  Surgery-based                    9        1.39 (1.16, 1.68), \<0.001   48.0, 0.05    0.60, 0.36    5    1.27 (1.07, 1.52), 0.007     26.9, 0.242   0.62, 0.69
  CRT                              3        1.44 (1.20, 1.72), \<0.001   0.0, 0.705    1.00, 0.94    --   --                           --            --
  Country                                                                                                                                            
  China                            9        1.42 (1.22, 1.66), \<0.001   48.8, 0.05    0.60, 0.22    4    1.29 (1.07, 1.55), 0.01      43, 0.15      0.73, 0.64
  Non-China                        3        1.31 (0.92, 1.86), 0.134     0.0, 0.68     1.00, 0.904   1    1.13 (0.66, 1.94), 0.66      --            --
  LMR                                                                                                                                                
  Overall                          6        0.70 (0.54, 0.89), 0.004     64.0, 0.02    0.02, 0.05    3    0.65 (0.43, 0.99), 0.04      75.2, 0.02    0.12, 0.06
  Cutoff value                                                                                                                                       
  ≥3.5                             3        0.80 (0.56, 1.10), 0.17      70.0, 0.04    1.00, 0.58    2    0.67 (0.33, 1.35), 0.26      86.9, 0.01    --
  \<3.5                            3        0.59 (0.46, 0.77), \<0.001   0.0, 0.54     0.30, 0.17    1    0.61 (0.42, 0.89), 0.01      --            --
  Sample size                                                                                                                                        
  ≥200                             4        0.83 (0.73, 0.95), 0.008     49.5, 0.11    0.09, 0.36    2    0.77 (0.50, 1.18)            67.1, 0.08    --
  \<200                            2        0.47 (0.32, 0.69), \<0.001   0.0, 0.70     --            1    0.46 (0.31, 0.69)            --            --
  Country                                                                                                                                            
  China                            5        0.74 (0.58, 0.93), 0.012     62.4, 0.03    0.03, 0.14    3    0.65 (0.43, 0.99), 0.04      75.2, 0.02    0.12, 0.06
  Non-China                        1        0.42 (0.21, 0.83), 0.013     --            --            0    --                           --            --
  Treatment                                                                                                                                          
  Surgery                          5        0.75 (0.59, 0.95), 0.017     58.4, 0.05    0.03, 0.12    2    0.77 (0.50, 1.18), 0.23      67.1, 0.08    --
  CRT                              1        0.50 (0.32, 0.78), 0.002     --            --            1    0.46 (0.31, 0.69), \<0.001   --            --

**Abbreviations:** CRT, chemoradiotherapy; CSS, cancer-specific survival; EFS, event-free survival; OS, overall survival; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; ESCC, esophageal squamous cell carcinoma.

###### 

Meta-analysis results of NLR, PLR, and LMR and clinicopathological parameters in patients with ESCC

                                                       NLR                                                   PLR                                                     LMR                                        
  ----------------------------------------------- ---- ---------------------------- ------------- ------ --- ---------------------------- --------------- ------ --- ---------------------------- ------------- ------
                                                                                                                                                                                                                
  Sex (M vs F)                                    12   1.58 (1.19, 2.10), 0.002     62.1, 0.002   0.63   7   0.84 (0.50, 1.44), 0.53      75.5, \<0.001   0.29   7   0.61 (0.37, 1.00), 0.049     75.1, 0.001   0.65
  Location (U/M vs L)                             11   1.01 (0.81, 1.26), 0.92      50.2, 0.02    0.63   7   1.00 (0.84, 1.20), 0.97      17.8, 0.29      0.88   7   1.23 (1.03, 1.46), 0.021     0.0, 0.71     0.65
  Tumor differentiation (poor vs moderate/high)   10   0.99 (0.76, 1.29), 0.66      63.9, 0.003   0.86   7   1.35 (1.03, 1.78), 0.03      44.3, 0.10      1.00   5   0.87 (0.60, 1.25), 0.44      58.9, 0.045   0.33
  Depth of invasion (T3--T4 vs T1--T2)            10   1.95 (1.46, 2.60), \<0.001   60.0, 0.007   0.86   6   1.49 (1.26, 1.76), \<0.001   0.0, 0.82       0.13   5   0.58 (0.48, 0.69), \<0.001   36.7, 0.18    0.33
  Tumor length (≥3 vs \<3 cm)                     3    2.82 (1.67, 4.77), \<0.001   63.1, 0.066   0.6    3   1.82 (1.32, 2.49), \<0.001   41.3, 0.18      0.60   3   0.86 (0.63, 1.18), 0.35      59.7, 0.08    0.6
  Lymph node metastasis (yes vs no)               11   1.27 (1.03, 1.57), 0.026     46.4, 0.045   0.21   8   1.53 (1.20, 1.96), 0.001     52.2, 0.04      1.00   6   0.68 (0.57, 0.82), \<0.001   0.0, 0.60     0.85
  Stage (III--IV vs I--II)                        10   1.47 (1.28, 1.69), \<0.001   0.0, 0.64     1.00   6   1.32 (1.12, 1.57), 0.001     11.1, 0.34      0.02   4   0.63 (0.50, 0.80), \<0.001   0.0, 0.48     0.09

**Abbreviations:** NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; ESCC, esophageal squamous cell carcinoma; M, male; F, female; U/M, upper/middle; L, lower.
